Conor Killmurray

For patients non–small cell lung cancer who previously progressed on chemotherapy and immune checkpoint inhibitors, ceralasertib plus durvalumab proved effective compared with patients with the same profile who received durvalumab alone, according to findings from the ongoing HUDSON study.

More than half of patients with T790M-positive non-small cell lung cancer had a response to the third generation EGFR TKI D-0316 in a phase 2 study.

Physicians published a new analysis that challenges the FDA approval of pembrolizumab for patients with treatment-refractory cancers and a high tumor mutational burden.

The RELATIVITY-047 study reached its primary endpoint for the fixed dose combination of relatlimab and nivolumab for patients with previously untreated metastatic or unresectable melanoma.

Data from the KEYNOTE-158 study, presented at the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer, showed durable responses in heavily pretreated patients with vulvar squamous cell carcinoma regardless of their PD-L1 status.

At the Society of Gynecological Oncology Virtual Annual Meeting on Women’s Cancer data from the phase II OVARIO study continued to show the progression free survival benefit for heavily pretreated patients with advanced ovarian cancer.

The FDA has granted a fast-track designation to the tyrosine kinase inhibitor, poziotinib for the treatment of previously treated patients with non-small cell lung cancer whose tumors harbor a HER2 exon 20 mutation.

At a panel at the ACCC 47th Annual Meeting and Cancer Center Business Summit, several oncology professionals discussed the many changes to cancer care that COVID-19 has accelerated and what challenges still lie ahead.

The phase 3 GENUINE study demonstrated a response benefit with the addition of the anti-CD20 monoclonal antibody ublituximab to ibrutinib for patients with relapsed or refractory high-risk chronic lymphocytic leukemia.

Updated data show a continued survival benefit for patients with metastatic renal cell carcinoma as the group reached the median overall survival endpoint for the phase II MERECA study.

The National Comprehensive Cancer Network released the first set of guidelines for pediatric patients with nephroblastoma for oncologists and primary care physicians.

Preliminary data showing the neoadjuvant use of cabozantinib and nivolumab to be feasible for borderline resectable patients with hepatocellular carcinoma that can lead to potentially curative resection.

Data from a prospective pilot trial presented at the 2021 Transplantation and Cellular Therapy Meetings show that a maximum dose of 10 mg of ruxolitinib given peri-transplant is a safe and feasible treatment for patients with myelofibrosis.

In the phase 1 RESILIENT trial, patients with small cell lung cancer who failed platinum-based treatment in the first-line setting, displayed encouraging anti-tumor activity and safety, results presented during the 2020 World Conference on Lung Cancer show.

The overall health-related quality of life among younger patients with colorectal cancer is poorer as incidence in patients under the age of 50 increases, with social and functional well-being suffering more with longer treatment durations.

Using 5- HT3 inhibitors and early intervention with loperamide was shown to manage gastrointestinal adverse events oral paclitaxel and encequidar in patients with metastatic breast cancer, according to a study presented during the San Antonio Breast Cancer Symposium.

Chimeric antigen receptor T-cell therapy with lisocabtagene maraleucel led to rapid and durable responses in patients with high-risk relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

The health-related quality of life had clinically meaningful improvements with pembrolizumab as a first-line therapy for patients with microsatellite instability-high and/or mismatch repair-deficient metastatic colorectal cancer versus standard-of-care chemotherapy, according to new data presented at the ESMO Virtual Congress 2020.

A pair of off-the-shelf CAR T-cell agents have shown promise for the treatment of relapsed/refractory large B-cell or follicular lymphoma, according to the phase 1 ALPHA study.